Short term adherence tool predicts failure on second line protease inhibitor-based antiretroviral therapy: An observational cohort study

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Court, Richard ^a   Leisegang, Rory ^a   Stewart, Annemie ^a   Sunpath, Henry ^b   Murphy, Richard ^c,e   Winternheimer, Philip ^d   Ally, Mashuda ^b   Maartens, Gary ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF EVANSVILLE   (United States)

^e MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

HIV; Medication adherence; Pharmacy refill; Second line antiretroviral therapy; Virologic failure

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SOUTH AFRICA; VIROLOGIC FAILURE; VIRUS LOAD; ANTIVIRAL RESISTANCE; HIV INFECTIONS; OUTPATIENT DEPARTMENT; TREATMENT FAILURE;

ADULT; AMBULATORY CARE FACILITIES; ANTI-HIV AGENTS; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MEDICATION ADHERENCE; RISK FACTORS; SOUTH AFRICA; TREATMENT FAILURE; VIRAL LOAD;

EID: 84923864472     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-014-0664-3     Document Type: Article

References (21)

1. Medecins Sans Frontiers Access Campaign; 2014. www.msfaccess.org/facts/hiv-aids?page=4. Accessed December 6, 2014.
2. Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N: Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS 2012, 26(8):929-938.
3. Sigaloff KCE, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, Botes M, Mandaliya K, Wellington M, Osibogun A, Stevens W, van Vugt M, de Wit R: Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa. J Infect Dis 2012, 205(11):1739-1744.
4. Napravnik S, Eron JJ, Sterling TR, Juday T, Uy J, Moore R: Outcomes of second combination antiretroviral therapy regimens among HIV-infected persons in clinical care: a multicentre cohort study. AIDS Res. Hum. Retroviruses 2013, 29(3):574-580.
5. Johnston V, Fielding K, Charalambous S, Mampho M, Churchyard G, Phillips A, Grant A: Second-line antiretroviral therapy in a workplace and community-based treatment programme in South Africa: determinants of virological outcome. PLoS One 2012, 7(5):e36997.
6. Win MM, Maek-A-Nantawat W, Phonrat B, Kiertiburanakul S, Sungkanuparph S: Virologic and immunologic outcomes of the second-line regimens of antiretroviral therapy among HIV-infected patients in Thailand. J Int Assoc Physicians AIDS Care (Chic) 2011, 10(1):57-63.
7. Fox MP, Ive P, Long L, Maskew M, Sanne I: High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010, 53(4):500-506.
8. Pujades-Rodríguez M, Balkan S, Arnould L, Brinkhof MA, Calmy A, AIDS Working Group of MSF: Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. JAMA 2010, 304(3):303-312.
9. Murphy R, Sunpath H, Castilla C, Ebrahim S, Court R, Nguyen H, Kuritzkes D, Marconi V, Nachega J: Second-line antiretroviral therapy: long-term outcomes in South Africa. J Acquir Immune Defic Syndr 2012, 61(2):158-163.
10. Wallis CL, Mellors JW, Venter WDF, Sanne I, Stevens W: Protease inhibitor resistance is uncommon in HIV-1 subtype C infected patients on failing second-Line lopinavir/r-containing antiretroviral therapy in South Africa. AIDS Res Treat. 2011, 2011:769627.
11. El-Khatib Z, Ekstrom AM, Ledwaba J, Mohapi L, Laher F, Karstaedt A, Charalambous S, Petzold M, Katzenstein D, Morris L: Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS 2010, 24(11):1679-1687.
12. Van Zyl GU, van Mens TE, McIlleron H, Zeier M, Nachega JB, Decloedt E, Malavazzi C, Smith P, Huang Y, van der Merwe L, Gandhi M, Maartens G: Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. J Acquir Immune Defic Syndr 2011, 56(4):333-339.
13. The World Health Organization: Consolidated Guidelines on the use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Recommendations for a Public Health Approach; 2013. www.who.int/hiv/pub/guidelines/arv2013/en/. Accessed July 6, 2013.
14. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, Regensberg L, Chaisson R, Maartens G: Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr 2006, 43(1):78-84.
15. Grossberg R, Zhang Y, Gross R: A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol 2004, 57(10):1107-1110.
16. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G: Adherence to nonnucleoside reverse transcriptase inhibitor - based HIV therapy and virologic outcomes. Annals of Internal 2007, 146(8):564-573.
17. Acri T, Grossberg R, Gross R: How long is the right interval for assessing anti-retroviral pharmacy refill adherence? J Acquir Immune Defic Syndr 2010, 54(5):e16-e18.
18. Murphy RA, Sunpath H, Lu Z, Chelin N, Losina E, Gordon M, Ross D, Ewusi AD, Matthews LT, Kuritzkes DR, Marconi VC, South Africa Resistance Cohort Study Team: Outcomes after virologic failure of first-line ART in South Africa. AIDS 2010, 24(7):1007-1012.
19. Grossberg R, Gross R: Use of pharmacy refill data as a measure of antiretroviral adherence. Curr HIV/AIDS Rep 2007, 4(4):187-191.
20. Martin M, Del Cacho E, Codina C, Tuset M, De Lazzari E, Mallolas J, Miró JM, Gatell JM, Ribas J: Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses 2008, 24(10):1263-1268.
21. Garone DB, Conradie K, Patten G, Cornell M, Goemaere E, Kunene J, Kerschberger B, Ford N, Boulle A, van Cutsem G: High rate of virological re-suppression among patients failing second-line antiretroviral therapy following enhanced adherence support: a model of care in Khayelitsha, South Africa. SA J HIV MED 2013, 14(4):166-169.